Detail akcie Prime Medicine Rg online

Business Summary: Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Prime Medicine Inc revenues increased from $800K to $3.8M. Net loss increased 1% to $155.1M. Revenues reflect BIOLOGICAL PRODUCTS segment increase from $209K to $2.3M. Higher net loss reflects BIOLOGICAL PRODUCTS segment loss increase of 98% to $107.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.34 to -$1.13.